Does Blue Cross Blue Shield of Texas Cover Jardiance?

What Is Jardiance and Why Does Coverage Matter?

Jardiance (empagliflozin) is an SGLT2 inhibitor approved by the FDA for type 2 diabetes, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and chronic kidney disease. Because it carries multiple cardiovascular and renal indications, it is one of the more clinically consequential drugs in the diabetic and cardiometabolic space. The FDA approved empagliflozin for type 2 diabetes in August 2014 and subsequently expanded its label for cardiovascular risk reduction in December 2016, following publication of the landmark EMPA-REG OUTCOME trial [1].

Coverage decisions by insurers like Blue Cross Blue Shield of Texas carry real clinical weight. In EMPA-REG OUTCOME (N=7,020), empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% versus placebo (hazard ratio 0.86 to 95% CI 0.74, 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [2]. Cardiovascular death alone fell by 38%. Patients who cannot afford Jardiance and lack a covered alternative face documented increases in hospitalization risk.

The American Diabetes Association (ADA) 2024 Standards of Care explicitly state: "In patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with proven cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization" [3]. That guideline language gives prescribers a strong foundation for prior authorization letters.

How BCBS Texas Formularies Work

BCBS Texas does not operate a single uniform formulary. The company administers dozens of distinct plan types, each with its own drug list. The main categories you will encounter include BlueChoice PPO plans (sold on and off the ACA marketplace), Blue Advantage HMO plans, FEP (Federal Employee Program) plans for government workers, and Blue Advantage Plus Medicare Advantage plans.

Every one of these plan types maintains a separate formulary, updated annually each January. Jardiance consistently appears on most BCBS Texas commercial formularies at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). The distinction matters because Tier 3 copays typically run $50, $90 for a 30-day supply after deductible, while Tier 4 copays can reach $100, $200 or higher for the same supply, depending on plan design [4].

To find your exact tier and cost-sharing amount, log into your member portal at bcbstx.com, manage to "Prescription Drug Coverage," and enter the drug name and dosage. Alternatively, call the member services number printed on the back of your insurance card and ask a representative to confirm both the formulary tier and any utilization management requirements.

Prior Authorization Requirements for Jardiance

Prior authorization (PA) is required by most BCBS Texas commercial plans before Jardiance will be covered at the in-network benefit level. The PA process exists because SGLT2 inhibitors are higher-cost branded medications and because insurers want to confirm the clinical indication is supported.

Typical PA criteria for Jardiance on BCBS Texas plans include a confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x), documented HbA1c above a threshold (commonly 7.5% or 8.0%), and evidence of prior use or intolerance of a first-line agent such as metformin. For the cardiovascular or heart failure indication, documentation of an established diagnosis (ICD-10 I50.x for heart failure or I25.x for chronic ischemic heart disease) is generally sufficient to bypass the diabetes-specific step therapy requirement.

The prescriber's office submits the PA request. Turnaround is typically 24 to 72 hours for standard reviews and 8 hours for urgent reviews under Texas Department of Insurance rules [5]. If you need Jardiance immediately while a PA is pending, most pharmacies can dispense a 72-hour emergency supply under Texas law.

The table below describes the four-step PA submission framework that HealthRX clinicians use when advocating for Jardiance coverage on behalf of patients.

Step 1: Confirm the clinical indication. Pull the most recent HbA1c, eGFR, echocardiogram (if heart failure), and urine albumin-to-creatinine ratio (UACR). An eGFR between 20 and 45 mL/min/1.73m² actually strengthens the case for Jardiance under the DAPA-CKD and EMPA-KIDNEY trial data [6].

Step 2: Document prior therapy. The PA form will ask whether the patient tried metformin. Document dose, duration, and reason for discontinuation if applicable. Lactic acidosis risk (eGFR <30) and GI intolerance are both recognized contraindications that justify skipping metformin.

Step 3: Attach guideline citations. Include the ADA 2024 Standards of Care, the 2022 AHA/ACC/HFSA Heart Failure Guideline, and the FDA label. Formulary reviewers are more likely to approve requests that cite named guidelines than those relying solely on clinical narrative [7].

Step 4: Request peer-to-peer review if denied initially. The prescriber can call the plan's medical director within 72 hours of a denial. A 10-minute peer-to-peer call citing EMPA-REG OUTCOME and the ADA class-level recommendation resolves a substantial proportion of initial denials.

Step Therapy and How to Manage It

Step therapy, sometimes called "fail first," requires trying a less expensive drug before the insurer will cover the preferred agent. For Jardiance, the most common step-therapy requirement on BCBS Texas plans is documented use of metformin for at least 90 days.

Texas enacted Senate Bill 680 in 2017, which prohibits step therapy from requiring a patient to fail a drug that is contraindicated, causes an adverse reaction, or was previously tried and found ineffective. This law applies to fully insured plans regulated by the Texas Department of Insurance [8]. Self-funded employer plans fall under ERISA and are not subject to Texas state step-therapy rules, which is a distinction worth confirming before you assume the law applies to your plan.

If metformin is contraindicated due to reduced kidney function, the prescriber should note the eGFR in the PA request. The FDA label for metformin contraindicates use when eGFR falls below 30 mL/min/1.73m², and it recommends dose reassessment when eGFR falls below 45 [9]. Patients with chronic kidney disease who meet those thresholds have a documented contraindication that should satisfy Texas step-therapy override rules.

For patients with established cardiovascular disease or heart failure as the primary indication for Jardiance, the cardiovascular indication may entirely bypass diabetes-related step therapy. The 2022 AHA/ACC/HFSA Heart Failure Guideline gives SGLT2 inhibitors a Class I recommendation (Level of Evidence A) for patients with heart failure and reduced ejection fraction, regardless of diabetes status [10]. That Class I, Level A designation is among the strongest recommendations in cardiology guidelines and gives prescribers a clear basis for PA approval without a diabetes diagnosis.

What Jardiance Costs Without Insurance or With a High Copay

The list price of Jardiance runs approximately $650, $700 for a 30-day supply at major retail pharmacies as of 2025. That price is not what most commercially insured patients pay, but it is what uninsured patients or those in a deductible phase pay if they present their insurance card without additional assistance.

Boehringer Ingelheim and Eli Lilly, the co-manufacturers of Jardiance, offer a Savings Card program for commercially insured, non-Medicare patients. Eligible patients may pay as little as $10 per month for up to 24 months, with a maximum savings cap of approximately $150 per prescription [11]. The card cannot be used with Medicare, Medicaid, or any government-funded program.

For Medicare Part D members on BCBS Blue Advantage Plus plans, Jardiance is typically covered at Tier 3 or Tier 4. The Inflation Reduction Act of 2022 capped out-of-pocket Part D costs at $2,000 per year beginning in 2025, which meaningfully reduces the annual burden for seniors on high-cost medications [12].

Patients who do not qualify for the copay card because they have Medicare may apply to the Lilly Cares Foundation or BI Cares patient assistance programs, both of which provide Jardiance at no cost to patients below 400% of the federal poverty level.

What to Do If BCBS Texas Denies Your Jardiance Claim

A denial letter is not a final answer. BCBS Texas, like all insurers operating in Texas, is required to provide a written explanation of the denial with the specific clinical criteria not met. Read that letter carefully before responding.

Your first option is an internal appeal. You have 180 days from the denial date to file with BCBS Texas. For a medical necessity denial, the appeal should include a physician letter citing the ADA 2024 Standards of Care [3], your most recent HbA1c or eGFR lab results, and if applicable, the EMPA-REG OUTCOME or EMPEROR-Reduced trial data [13]. Approximately 40 to 60% of internal appeals for specialty medications are overturned when adequately documented, based on data from the Kaiser Family Foundation's 2023 analysis of ACA marketplace insurer appeals [14].

Your second option, if the internal appeal fails, is an external independent medical review. Texas law entitles fully insured plan members to an independent review by a third-party reviewer not affiliated with BCBS Texas. The Texas Department of Insurance oversees this process, and decisions rendered by independent reviewers are binding on the insurer [5].

Your prescriber can also request a peer-to-peer review with the BCBS Texas medical director at any point before or during the appeals process. This is often the fastest path to reversal for a clinically well-documented case.

Comparing Jardiance to Covered Alternatives

If your BCBS Texas plan does not cover Jardiance or places it at a tier that makes it unaffordable even with the copay card, your prescriber may consider other SGLT2 inhibitors or related agents that sit at a lower formulary tier.

Dapagliflozin (Farxiga) is the most clinically comparable alternative. The DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with heart failure and reduced ejection fraction (HR 0.74 to 95% CI 0.65, 0.85, P<0.001) [15]. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes versus placebo [6]. Dapagliflozin is sometimes placed at a lower tier than empagliflozin depending on BCBS Texas plan negotiation with AstraZeneca.

Canagliflozin (Invokana) is a third SGLT2 inhibitor option. The CREDENCE trial (N=4,401) demonstrated a 30% reduction in the composite renal outcome compared to placebo in patients with type 2 diabetes and diabetic kidney disease [16]. Canagliflozin carries a higher risk of lower-limb amputation than the other agents in the class, a black box warning that some prescribers treat as a reason to prefer empagliflozin or dapagliflozin.

If your prescriber determines that Jardiance is clinically superior to alternatives for your specific situation, that clinical rationale should be documented explicitly in the PA request. Formulary reviewers can consider step exceptions when the alternative drug poses a documented clinical risk.

Medicare Part D and Jardiance on BCBS Blue Advantage Plus

BCBS Texas administers several Medicare Advantage plans under the Blue Advantage Plus brand. Jardiance is covered on these Medicare Part D formularies, though the tier placement and cost-sharing structure differ from commercial plans.

On Medicare Part D plans, the Inflation Reduction Act of 2022 introduced a $35 per month cap on covered insulin products beginning in 2023, but Jardiance does not qualify for that insulin-specific cap. Instead, the broader $2,000 out-of-pocket maximum that takes effect in 2025 under the IRA applies to all Part D covered drugs including Jardiance, giving Medicare patients meaningful annual cost protection for the first time [12].

Medicare patients should also be aware that the Low Income Subsidy (LIS), also called Extra Help, can reduce Jardiance copays to $4.50, $11.20 per month for qualifying individuals. Eligibility is based on income and assets, and applications are processed through the Social Security Administration.

How to Confirm Your Coverage Before Filling

The three fastest ways to confirm your specific Jardiance coverage under your BCBS Texas plan are: call member services using the number on your insurance card and request a formulary benefit check by drug name and NDC; log into the BCBS Texas member portal at bcbstx.com and use the prescription drug lookup tool; or ask your pharmacy to run a test claim before you commit to picking up the prescription.

A test claim run by your pharmacist will show the exact copay you owe at your current benefit stage, whether prior authorization is flagged, and whether a quantity limit applies. This takes under two minutes and costs you nothing.

If prior authorization is flagged, ask your prescriber's office to submit the PA the same day. Most BCBS Texas plans allow a 72-hour emergency override while the PA is under review, meaning you may be able to pick up at least a partial supply immediately.

Kidney Disease and the EMPA-KIDNEY Trial

Patients with chronic kidney disease represent a growing group for whom Jardiance coverage is especially time-sensitive. The EMPA-KIDNEY trial (N=6,609) was published in the New England Journal of Medicine in 2023 and showed that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% versus placebo (HR 0.72 to 95% CI 0.64, 0.82, P<0.001) [17]. The trial included patients with eGFR as low as 20 mL/min/1.73m² and enrolled patients both with and without diabetes.

The FDA approved a new indication for Jardiance in chronic kidney disease to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in July 2023 [18]. This FDA label expansion gives prescribers a documented regulatory basis for Jardiance PA requests in patients with CKD who do not have diabetes, a group where step therapy requirements based on diabetes medication history are clinically irrelevant.

Citing the CKD FDA indication and the EMPA-KIDNEY N=6,609 data directly in a PA denial appeal has a strong track record of success at HealthRX, particularly for BCBS Texas commercial plans that updated their coverage criteria after the July 2023 FDA approval.